Skip Navigation



JAC Advance Access published online on August 8, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl333
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/4/733    most recent
dkl333v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Turner, A. K.
Right arrow Articles by Wain, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turner, A. K.
Right arrow Articles by Wain, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received April 27, 2006
Revised July 18, 2006
Accepted July 19, 2006

Original article

The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets

Arthur K. Turner 1, Satheesh Nair 1, and John Wain 1 *

1 The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK

* To whom correspondence should be addressed.
John Wain, E-mail: jw5{at}sanger.ac.uk


  Abstract

Objectives: To determine the contribution to fluoroquinolone resistance of point mutations in the gyrA and parC genes of Salmonella Typhi.

Methods: Point mutations that result in Ser-83->Phe, Ser-83->Tyr and Asp-87->Asn amino acid substitutions in GyrA and Glu-84->Lys in ParC were introduced into a quinolone-susceptible, attenuated strain of Salmonella Typhi using suicide vector technology. This is the first time that this approach has been used in Salmonella and abrogates the need for selection with quinolone antibacterials in the investigation of resistance mutations.

Results: A panel of mutants was created using this methodology and tested for quinolone resistance. The ParC substitution alone made no difference to quinolone susceptibility. Any single GyrA substitution resulted in resistance to nalidixic acid (MIC ≥ 512 mg/L) and increased by up to 23-fold the MIC of the fluoroquinolones ofloxacin (MIC ≤ 2 mg/L) ciprofloxacin (MIC ≤ 1 mg/L) and gatifloxacin (MIC ≤ 0.38 mg/L). Among the double substitution mutants, those with a substitution in ParC were less prone to killing with ciprofloxacin. The triple substitution mutants (Ser-83->Phe or Tyr and Asp-87->Asn in GyrA with Glu-84->Lys in ParC) showed high levels of resistance to all the fluoroquinolones tested (MICs: gatifloxacin, 3-4 mg/L; ofloxacin, 32 mg/L; ciprofloxacin, 32-64 mg/L).

Conclusions: In Salmonella Typhi the fluoroquinolones tested act on GyrA and, at higher concentrations, on ParC. The point mutations conferred reduced susceptibility to ofloxacin and ciprofloxacin, and also reduced susceptibility to gatifloxacin. Three mutations conferred resistance to ofloxacin (32 mg/L), ciprofloxacin (32 mg/L) and to the more active fluoroquinolone gatifloxacin (MIC ≥ 3 mg/L). These results predict that the use of ofloxacin or ciprofloxacin will select for resistance to gatifloxacin in nature.

Keywords: typhoid fever; antibiotic resistance; fluoroquinolones; nalidixic acid; ofloxacin; ciprofloxacin; gatifloxacin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
D. Thaver, A. K M Zaidi, J. Critchley, A. Azmatullah, S. A. Madni, and Z. A Bhutta
A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis
BMJ, June 3, 2009; 338(jun02_1): b1865 - b1865.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. K. Morgan-Linnell, L. Becnel Boyd, D. Steffen, and L. Zechiedrich
Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates
Antimicrob. Agents Chemother., January 1, 2009; 53(1): 235 - 241.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. A. Webber, L. P. Randall, S. Cooles, M. J. Woodward, and L. J. V. Piddock
Triclosan resistance in Salmonella enterica serovar Typhimurium
J. Antimicrob. Chemother., July 1, 2008; 62(1): 83 - 91.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. Baker, K. Holt, E. van de Vosse, P. Roumagnac, S. Whitehead, E. King, P. Ewels, A. Keniry, F.-X. Weill, D. Lightfoot, et al.
High-Throughput Genotyping of Salmonella enterica Serovar Typhi Allowing Geographical Assignment of Haplotypes and Pathotypes within an Urban District of Jakarta, Indonesia
J. Clin. Microbiol., May 1, 2008; 46(5): 1741 - 1746.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. K. Morgan-Linnell and L. Zechiedrich
Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coli
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4205 - 4208.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.